Results 81 to 90 of about 2,022,996 (246)

Detection of neoantigen-specific T cells following a personalized vaccine in a patient with glioblastoma

OncoImmunology, 2019
Neoantigens represent promising targets for personalized cancer vaccine strategies. However, the feasibility of this approach in lower mutational burden tumors like glioblastoma (GBM) remains unknown.
Tanner M. Johanns, Christopher A. Miller, Connor J. Liu, Richard J. Perrin, Diane Bender, Dale K. Kobayashi, Jian L. Campian, Michael R. Chicoine, Ralph G. Dacey, Jiayi Huang, Edward F. Fritsch, William E. Gillanders, Maxim N. Artyomov, Elaine R. Mardis, Robert D. Schreiber, Gavin P. Dunn   +15 more
doaj   +1 more source

A multilevel perspective on MSH6‐associated Lynch syndrome: Integrating molecular, biological, and clinical insights

International Journal of Cancer, EarlyView.
Abstract Lynch syndrome (LS) is the most common hereditary colorectal cancer syndrome, caused by a germline pathogenic variant in one of the mismatch repair (MMR) genes. Among these, MSH6‐associated LS represents a distinct subtype with unique molecular and clinical characteristics.
Salwa Ben Yahia, Anne‐Sophie van der Werf‐'t Lam, Madalina Cabuta, Maartje Nielsen, Noah C. Helderman   +4 more
wiley   +1 more source

Pan-cancer analysis of PDZK1IP1 reveals its role in tumorigenesis and tumor immunity: focused validation in thyroid carcinoma

Hereditas
Background PDZK1IP1 is a membrane protein linked to inflammation and cancer, but its role in the tumor immune microenvironment is poorly understood. This study systematically investigated the oncogenic and immunological functions of PDZK1IP1 via a pan ...
Chenchen Geng, Xiaoqian Gao, Yali Le, Shuzhen Zhu, Guanghui Zhao, Ping Zhang   +5 more
doaj   +1 more source

Cysteine Peptidases in Antitumor Immunity: Unraveling Antigen‐Presenting Cell Regulation and Therapeutic Potential

iMetaMed, EarlyView.
This review systematically summarizes the central role of cysteine peptidases in modulating antigen‐presenting cell (APC) function and antitumor immune responses, highlighting their critical significance in overcoming tumor immune evasion. Current research has established that cysteine peptidase subtypes, including cathepsins B, S, L, and X, exert ...
Yimao Wu, Xiaoyan Chen, Zichang Chen, Yalun Liang, Gokhan Zengin, Qian Zhang, Wenlong Sun, Meng‐Yao Li   +7 more
wiley   +1 more source

Oncolytic adenovirus delivery of neoantigens sensitizes low-mutation tumors to anti-PD-1 therapy and prevents metastasis

Signal Transduction and Targeted Therapy
Neoantigen vaccines and oncolytic viruses are emerging immunotherapies that can reshape the tumor microenvironment (TME). However, tumors with low mutation burdens often respond poorly to immunotherapies because of their limited immunogenicity ...
Ke-Yu Shen, Shi-Zhe Yu, Ying-Han Su, Sun-Zhe Xie, Chen Zhang, Hao Xu, SamI Yang, Tian-Tian Zou, Yan Fu, Hao Wang, Lin Fang, Yan Zheng, Chang-Qing Su, Lun-Xiu Qin   +13 more
doaj   +1 more source

A method for identifying neoantigens through isolation of circulating tumor cells using apheresis among patients with advanced-stage cancer

Frontiers in Immunology
BackgroundImmune checkpoint inhibitors show limited efficacy in tumors with low tumor mutational burden, partly due to insufficient neoantigen presentation.MethodsWe developed a novel approach for neoantigen identification using circulating tumor cells ...
Daiki Kobayashi, Daiki Kobayashi, Takuya Kosumi, Queenie Lai Kwan Lam, Shigeharu Fujita, Yasuki Hijikata, Kaori Takeda, Tomoya Narita, Naomi Yamashita, Guilhem Richard, Anne S. De Groot, Naohide Yamashita   +11 more
doaj   +1 more source

Data from Tumor Burden Dictates the Neoantigen Features Required to Generate an Effective Cancer Vaccine

<div>Abstract<p>Tumor neoantigens (nAg) represent a promising target for cancer immunotherapy. The identification of nAgs that can generate T-cell responses and have therapeutic activity has been challenging. Here, we sought to unravel the features of nAgs required to induce tumor rejection.
Anna Morena D'Alise, Elisa Scarselli, Valeria Poli, Massimo Mallardo, Carmen Caiazza, Laura Conti, Giuseppina Romano, Simona Allocca, Gabriella Cotugno, Laura Antonucci, Laura Seclì, Guido Leoni, Fulvia Troise, Lidia Avalle, Linda Nocchi, Irene Garzia   +15 more
openaire   +1 more source

The T‐Cell Response Mechanism in Human Papillomavirus‐Associated Cervical Cancer and New Strategies for Immunotherapy

iNew Medicine, EarlyView.
ABSTRACT Human papillomavirus (HPV) is a double‐stranded DNA virus that infects human skin and mucosal tissues exclusively. The German scientist Harald zur Hausen was awarded the 2008 Nobel Prize in Physiology or Medicine for his discovery of the link between HPV infection and cervical cancer.
Fang Zhu, Farah Nazir, Ying Zhou, Yuhua Shang, Hongliang He, Tengchuan Jin   +5 more
wiley   +1 more source

An oncogene regulating chromatin favors response to immunotherapyOncogene CHAF1A and immunotherapy outcomes

OncoImmunology
Many biological processes related to cell function and fate begin with chromatin alterations, and many factors associated with the efficacy of immune checkpoint inhibitors (ICIs) are actually downstream events of chromatin alterations, such as genome ...
Leqian Ying, Zhangmin Hu, Yi Lu, Qing Tao, Fen Xiong, Yongqian Shu, Yufei Yang, Xuehan Qiao, Chen Peng, Yuchun Jiang, Miao Han, Min Xu, Xiaoqin Li, Deqiang Wang   +13 more
doaj   +1 more source

Generalization of neoantigen-based tumor vaccine by delivering peptide-MHC complex via oncolytic virus

Neoantigen vaccine is a promising breakthrough in tumor immunotherapy. However, the application of this highly personalized strategy in the treatment of solid tumors is hindered by several obstacles, including very costly and time-consuming preparation ...
Xiaolong Liu, Junjie Xie, Yingjun Shi, Da Zhang, Bingchen Wu, Chenyi Wang, Cuilin Zhang, Yupeng Sun   +7 more
core   +1 more source